|To join The Indian
American Chemical Society (TIACS), Please send an email to: TIACSemail@example.com
5109 Kali Era, Sarvajit
Vikramarka Era, Sarvajit
2007 AD, July
Home of American Innovation
If travel to the Washington DC area is in your plans for July and August,
include a visit to the historic home of American innovation, the United
States Patent and Trademark Office (USPTO). The USPTO is located in Alexandria,
Virginia and is near two subway stops--King Street and Eisenhower Avenue.
All this summer the USPTO is featuring an exhibit of the year's 25 best inventions
as selected by the History Channel and Time Magazine. "The Modern Marvels"
exhibit is free and open to the public Monday through Friday from 9 a.m.
to 5 p.m. and on Saturdays from noon to 5 p.m. The exhibit is located in
the atrium of the Madison Building just outside the USPTO museum. For more
information on visiting the USPTO and current exhibits call 571-272-0095. http://www.uspto.gov/
A bill aiming to reform the United States' patent law cleared an important
hurdle when it was unanimously passed by the House Judiciary Committee after
a markup session.
The Board of Patent Appeals and Interferences recently signaled a dramatic
shift in how the PTO will deal with the obviousness question and may have
raised the obviousness bar at the PTO in practice for certain predictable
On July 9, 2007, OMB concluded its review of the Continuations and Claims
rule changes. The final rules will be made public when they are published
in the Federal Register, which is expected to be later this summer. The
rules will become effective at least 60 days after publication in the Federal
Register, and no earlier than October 1, 2007.
Doctrine of Equivalents
In a precedent-setting case over when a patent owner could claim infringement
under the doctrine of equivalents, the Federal Circuit ruled that SMC Corp.
did not infringe a Festo Corp. patent for rodless cylinders because SMC's
device was foreseeable and prosecution history estoppel applied. http://www.patentlyo.com/patent/2007/07/further-limitat.html
AstraZeneca is whacking 7,600 workers off the payroll as it steps up its
restructuring plans. That amounts to 11 percent of its work force. Determined
to find $900 million in savings by 2010, CEO David Brennan says these cuts
would hit the company's European sales and marketing operations along with
R&D in a variety of countries around the globe. The cuts were announced
with a second quarter earnings report that analysts regard as more evidence
of a fundamentally strong company. AstraZeneca bought Cambridge Antibody
Technology Group recently to help add to its portfolio of experimental therapies.
AstraZeneca is also transferring some of its business to China in an attempt
to keep a lid on costs.
No Need for New Drugs!
Older, cheaper medications for type 2 diabetes appear to be as good as
newer drugs. In a study published online in the Annals of Internal Medicine,
researchers looked at data from more than 200 published studies as well
as unpublished information from drug companies and the Food and Drug Administration
on oral diabetes drugs. Metformin, an older, cheap generic drug, did particularly
well compared to other medications, it worked just as well, without causing
the side effects of weight gain or blood sugar lows seen with other new
drugs. Metformin also lowered bad cholesterol levels, while some newer drugs
such as Avandia and Actos raised cholesterol levels. Actos and Avandia also
significantly increased the risk of heart failure, the study found. Avandia
has also been under scrutiny after studies published last May suggested
the drug increased the risk of heart attacks. Medicines Sans Frontiers need
not go after patented drugs and break patents! Poor and rich people in this
world are better served with older drugs.
Early in July, the government of China set out its ambitious five-year
goals for the development of biotechnology. The aim of the initiative is
to make China a biotech powerhouse by 2020, increasing biotech revenues
to a full 4% of Chinese GDP at that time. These are aggressive plans. To
get to that point, China will build on its base of independent innovation,
combining it with cooperation with international biotech. Its guiding principle
for growth, according to the document, is: “Led by the market, supported
by the government.”
The leaders of the biotechnology industry will once again gather for BIO-Europe,
the world’s largest stand-alone partnering conference, in Hamburg, Germany
(November 12-14). This year’s edition promises to set a new standard for compelling
and informative content necessary to discern opportunities in an era of significant
biotech industry change. Join many of the most respected thought leaders
and decision makers in the industry and examine the issues, new business
approaches and policy trends most important to the emerging biotech future.
A central theme to BIO-Europe 2007 will be to understand the signs, symptoms
and opportunities of the much-anticipated convergence of biotech and Big Pharma.
Fundamental questions, such as how can biotechnology companies help the pharmaceutical
industry meet double digit growth expectations by contributing new products
and processes, will be openly discussed and debated by some of the most notable
names in the industry. A session destined to shake up traditional wisdom
and preconceived notions of the industry is entitled, “The Changing World
Order of Biotech-Pharma – How Will Emerging Realities Affect Your Business
Full article click here.
Publishing cutting-edge research that reduces the environmental impact of
the chemical enterprise by developing alternative sustainable technologies.
Green Chemistry Links
Source: The primary sources cited
above, BBC News, New York Times
(NYT), Washington Post (WP), Mercury
News, Bayarea.com, Chicago Tribune, USA
Today, Intellihealthnews, Deccan Chronicle
(DC), the Hindu, Hindustan Times,
Times of India, AP, Reuters, AFP, womenfitness.net,
Notice: The content of the articles is intended
to provide general information. Specialist advice should be sought
about your specific circumstances.